ZA201603118B - Compounds for use in prevention and treatment of neurodegenerative diseases and pain - Google Patents

Compounds for use in prevention and treatment of neurodegenerative diseases and pain

Info

Publication number
ZA201603118B
ZA201603118B ZA2016/03118A ZA201603118A ZA201603118B ZA 201603118 B ZA201603118 B ZA 201603118B ZA 2016/03118 A ZA2016/03118 A ZA 2016/03118A ZA 201603118 A ZA201603118 A ZA 201603118A ZA 201603118 B ZA201603118 B ZA 201603118B
Authority
ZA
South Africa
Prior art keywords
pain
prevention
compounds
treatment
neurodegenerative diseases
Prior art date
Application number
ZA2016/03118A
Other languages
English (en)
Inventor
Jim-Min Fang
Yun-Lian Lin
Jung-Hsin Lin
Chun-Jung Lin
Yijuang Chern
Nai-Kuei Huang
Hung-Li Wang
Benjamin Pang-Hsien Tu
Chih-Cheng Chen
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of ZA201603118B publication Critical patent/ZA201603118B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/167Purine radicals with ribosyl as the saccharide radical
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ZA2016/03118A 2013-10-23 2016-05-10 Compounds for use in prevention and treatment of neurodegenerative diseases and pain ZA201603118B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361894699P 2013-10-23 2013-10-23
PCT/US2014/061734 WO2015061426A1 (en) 2013-10-23 2014-10-22 Compounds for use in prevention and treatment of neurodegenerative diseases and pain

Publications (1)

Publication Number Publication Date
ZA201603118B true ZA201603118B (en) 2019-04-24

Family

ID=52993493

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2016/03118A ZA201603118B (en) 2013-10-23 2016-05-10 Compounds for use in prevention and treatment of neurodegenerative diseases and pain

Country Status (14)

Country Link
US (1) US10301348B2 (enExample)
EP (1) EP3060566B1 (enExample)
JP (1) JP6534997B2 (enExample)
KR (1) KR102313314B1 (enExample)
CN (1) CN106414456B (enExample)
AU (1) AU2014340114B2 (enExample)
BR (1) BR112016008901B1 (enExample)
CA (1) CA2927699C (enExample)
IL (1) IL245103B (enExample)
MX (1) MX367707B (enExample)
RU (1) RU2695358C2 (enExample)
SG (1) SG11201603063WA (enExample)
WO (1) WO2015061426A1 (enExample)
ZA (1) ZA201603118B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2978521A1 (en) * 2015-05-29 2016-12-08 National Yang-Ming University Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes
EP3573996B1 (en) * 2017-01-27 2022-06-15 Academia Sinica Compound with analgesic effect for use in prevention and treatment of pain
CA3250090A1 (en) * 2022-02-10 2023-08-17 Academia Sinica METHOD FOR TREATMENT OF A SPINAL CORD INJURY AND CORRESPONDING COMPOSITION
EP4551229A1 (en) * 2022-07-07 2025-05-14 Academia Sinica Method of treating schizophrenia and composition for use therein
EP4642452A1 (en) * 2022-12-29 2025-11-05 Academia Sinica Method of treating sleep disruptions and composition for use therein
AU2024241207A1 (en) * 2023-03-17 2025-10-09 Academia Sinica Method of treating tuberous sclerosis complex or epilepsy and composition for use therein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8274187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
US5034381A (en) * 1988-01-07 1991-07-23 Ciba-Geigy Corporation 2-(substituted amino) adenosines as antihypertensives
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
WO1992005177A1 (en) * 1990-09-25 1992-04-02 Rhone-Poulenc Rorer International (Holdings) Inc. Compounds having antihypertensive and anti-ischemic properties
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
TWI398255B (zh) 2009-11-13 2013-06-11 Academia Sinica 結合至腺苷酸aa受體和腺苷酸轉運子以預防及治療神經退化疾病的雙功能化合物
CN102812033B (zh) 2009-12-10 2015-11-25 中国医学科学院药物研究所 N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途
CA2862750C (en) * 2012-02-09 2015-11-17 Brandbumps, Llc Decorative detectable warning panel having improved grip
WO2013120078A1 (en) * 2012-02-11 2013-08-15 Academia Sinica Methods and compositions for treating pain

Also Published As

Publication number Publication date
IL245103B (en) 2019-02-28
KR20160086852A (ko) 2016-07-20
MX367707B (es) 2019-09-03
AU2014340114A1 (en) 2016-05-26
JP2016535019A (ja) 2016-11-10
WO2015061426A1 (en) 2015-04-30
IL245103A0 (en) 2016-06-30
CN106414456A (zh) 2017-02-15
EP3060566A1 (en) 2016-08-31
BR112016008901A2 (pt) 2020-05-12
RU2016118282A (ru) 2017-11-28
US20160264613A1 (en) 2016-09-15
RU2016118282A3 (enExample) 2018-06-18
US10301348B2 (en) 2019-05-28
RU2695358C2 (ru) 2019-07-23
NZ719740A (en) 2021-02-26
CA2927699A1 (en) 2015-04-30
AU2014340114B2 (en) 2018-10-18
JP6534997B2 (ja) 2019-06-26
CA2927699C (en) 2022-07-05
KR102313314B1 (ko) 2021-10-19
SG11201603063WA (en) 2016-05-30
EP3060566B1 (en) 2018-09-05
CN106414456B (zh) 2018-12-14
EP3060566A4 (en) 2017-06-14
MX2016005174A (es) 2016-08-11
BR112016008901B1 (pt) 2022-08-23

Similar Documents

Publication Publication Date Title
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
PL3031826T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
HUE039560T2 (hu) Mikro méretû zárófedés és kapcsolódó eljárások bõr kezelésére
GB201320729D0 (en) Therapeutic compounds and their use
IL239735A0 (en) Treatment and diseases associated with toxic aldehyde
SG10201709090UA (en) Sobetirome in the treatment of myelination diseases
IL239851B (en) Methods and compositions for treating diseases that act to remove myelin
EP2948195A4 (en) INCLUDED DEVICES FOR THE TREATMENT OF MEDICAL WASTE AND METHOD FOR THE USE THEREOF
GB201311361D0 (en) Compounds and their therapeutic use
ZA201603118B (en) Compounds for use in prevention and treatment of neurodegenerative diseases and pain
IL246036A0 (en) A therapeutic and/or prophylactic substance containing a derivative of 1-indensulfamide for pain
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
ZA201603117B (en) Withanolides useful for the treatment of neurodegenerative diseases
PL3228313T3 (pl) Postacie dawkowania i zastosowania terapeutyczne L-4-chlorokineureniny
GB201308736D0 (en) Compounds and their therapeutic use
ZA201506396B (en) Use of sedoheptulose for prevention or treatment of inflammation
EP3104869A4 (en) Treatment of pain
EP2964227A4 (en) TREATMENT AND PROPHYLAXIS OF RENAL DISEASES
IL259383A (en) A compound for use in the prevention and treatment of neurodegenerative diseases
HUP1300454A2 (hu) Daganatos betegségek gyógyítására és megelõzésére alkalmas gyógyászati készítmények, és eljárás azok elõállítására
GB201317373D0 (en) Treatment and prevention of cancer
GB201309001D0 (en) Methods for prevention and treatment of preeclampsia
GB201317804D0 (en) Therapeutic compounds and their use
GB201316173D0 (en) Compounds and their therapeutic use
GB201307677D0 (en) Compounds and their therapeutic use